Revenue grew 41% in Q3 and 42% for the nine months, while net loss remained high but stable. A fully guaranteed rights issue secured 9.9 MSEK, supporting continued expansion into diagnostics and lung cancer research.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.